Home » Topics » Disease categories and therapies » Urology

Urology
RSS

First patient dosed in pivotal phase III PROTECT study of sparsentan

Dec. 28, 2018

Antiviral response damages kidney in bacterial sepsis

Dec. 14, 2018

New phase IIb trial investigates efficacy of male contraceptive gel

Nov. 29, 2018

Dimerix begins dosing in phase II trials of DMX-200 for kidney disease

Nov. 23, 2018

Nash Pharmaceuticals reports data on NP-135 in mouse model of kidney fibrosis

Nov. 20, 2018

Calliditas begins phase III study of Nefecon in IgA nephropathy

Nov. 14, 2018

Swedish Medical Products Agency allows initiation of phase I trial of ROSgard

Nov. 13, 2018

Mutations in DKGE cause C3 glomerulopathy

Nov. 12, 2018

Purinergic receptor mutations cause congenital neurogenic bladder

Nov. 12, 2018

Visterra initiates first-in-human study with VIS-649 for IgA nephropathy

Nov. 8, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...